Cure Ventures, a Boston, MA-based life sciences venture capital firm, closed its $350M maiden fund.
The fund is supported by a syndicate of both U.S. and internationally-based investors that include state and city public pension funds, foundations and endowments, fund-of-funds, hospital and health systems, sovereign wealth funds and family offices.
Founded in 2021 and led by Managing Partners Lou Tartaglia, Richard Lim and David Fallace, Cure Ventures is a life sciences venture capital firm focused on de novo company formation around groundbreaking curative technologies. Its investment thesis is founded on three tenets:
- A seed funding model that allows Cure to de-risk the science and set companies up for success,
- genetic validation that increases the probability of success, and
- embedded Cure operators to drive the best day-to-day decision making in collaboration with founders.
FinSMEs
04/04/2023